Company Announcements

Hikma Pharmaceuticals PLC

Outcome of Audit Tender Process

LONDON, 7 November 2024 - Hikma Pharmaceuticals PLC ('the Company' or 'Hikma') announces that, following the completion of a formal competitive audit tender process, the Board of Directors has approved the reappointment of PricewaterhouseCoopers LLP ('PwC') as the external auditor of Hikma from 2026 onwards. 

As a UK public interest entity, Hikma is required to carry out an audit tender every 10 years and rotate the external auditor every 20 years. We disclosed in our 2023 Annual Report & Accounts the intention to commence an audit tender, given PwC were initially appointed for the audit of the 2016 Annual Report & Accounts.

Further details of the audit tender process will be included in our 2024 Annual Report & Accounts. This appointment is subject to shareholder approval at the 2026 Annual General Meeting.

- ENDS -

Enquiries

About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)

(LEI: 549300BNS685UXH4JI75)